Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
17 févr. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
07 janv. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Present at J.P. Morgan Healthcare Conference
06 janv. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
11 déc. 2020 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in the JMP Securities Hematology Summit
10 déc. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
08 déc. 2020 20h22 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Commencement of Public Offering of Common Stock
07 déc. 2020 16h01 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
05 déc. 2020 12h30 HE
|
Kura Oncology, Inc.
– Evidence of biologic activity observed in each dose-escalation cohort treated to date – – Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a...
Kura Oncology to Host Virtual Investor Event on December 5, 2020
24 nov. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Third Quarter 2020 Financial Results
05 nov. 2020 07h30 HE
|
Kura Oncology, Inc.
– Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH – – Encouraging safety, tolerability and activity with KO-539 highlighted in ASH abstract...